Objective-The arterial media, populated by vascular smooth muscle cells (VSMC), is an immunoprivileged compartment and, in contrast to the intima or adventitia containing endothelial cells, is generally spared by inflammatory processes, such as arteriosclerosis. To determine mechanisms of medial immunoprivilege, we investigated the ability of human VSMC versus endothelial cells to activate allogeneic T cells in vitro.
T he most common cause of death for cardiac transplant patients is chronic rejection characterized by pathological remodeling of coronary arteries. 1 Immunohistological analyses of arteriosclerotic lesions in transplanted hearts reveal an uneven distribution of infiltrating leukocyte within the vessel wall. T cells are predominantly localized in the intima and adventitia, whereas few reside within the medial layer. 1, 2 Similarly, in atherosclerosis of native (untransplanted) hearts, large numbers of leukocytes accumulate in the intima and adventitia, whereas the media is relatively free from leukocytic infiltrates. 3 These observations in diseased vessels are mirrored in murine viral infection models, suggesting that the arterial media is an immunoprivileged site. 4 Because vascular smooth muscle cells (VSMC) are the principal and almost exclusive cell type normally found in the media of noninflamed arteries, we have explored the hypothesis that VSMC are responsible for establishing medial immunoprivilege. In contrast, endothelial cells (EC), which normally line the intima and the adventitial microvessels, are generally accepted as playing prominent proimmunogenic roles. T cells, resident in normal arteries or infiltrating diseased arteries, normally recognize foreign antigens as a complex formed by antigenic peptides bound to self allelic forms of major histocompatibility complex (MHC) molecules expressed on the surface of antigen-presenting cells. A large percentage of T cells can cross-react with complexes formed by (often self) peptides with nonself allelic forms of MHC molecules, a phenomenon known as direct recognition of alloantigens. After pretreatment with interferon (IFN)-␥ to reinduce MHC class II molecules, cultured human EC present alloantigen and activate allogeneic memory CD4 T cells. 5 On IFN-␥ stimulation, cultured human VSMC are induced to express similar levels of MHC class II antigens as EC but fail to activate allogeneic memory CD4 T cells. 6, 7 In fact, IFN-␥-treated, but not untreated, VSMC can actively suppress the proliferation of CD4 T cells induced by EC by acting across a transwell. 6 Recently, we have shown that the tryptophanmetabolizing enzyme, indoleamine 2,3-dioxygenase (IDO) is highly induced by IFN-␥ in VSMC and that tryptophan depletion in the microenvironment by IDO inhibits T-cell accumulation in the media. 7 Although inhibiting IDO or supplementing cultures with L-tryptophan can abrogate the inhibitory transacting effects of IFN-␥-treated VSMC, it is not sufficient to allow VSMC to directly activate allogeneic CD4 T cells, suggesting additional immunomodulatory mechanisms in these cellular interactions. 7 In addition to TCR engagement with antigen-bound MHC molecules, full activation of T cells requires costimulatory signals. 8 Unlike professional antigen-presenting cells, such as dendritic cells, which predominantly use B7 molecules to costimulate T cells, human EC act as semiprofessional antigen-presenting cells and use alternative costimulatory molecules, such as leukocyte function-associated antigen-3, OX40 ligand (OX40L), and inducible costimulator ligand (ICOSL). This combination of costimulatory molecules allows EC to activate allogeneic memory CD4 and CD8 T cells, but not naïve T cells. 5 In this study, we have further investigated the interactions between human VSMC and allogeneic memory CD4 and CD8 T cells. Our data suggest that the inability of cultured VSMC to activate T cells results from a combination of IDO expression and a lack of OX40L expression.
Methods

Cells
Cells and tissues were obtained under protocols approved by the Yale University Human Investigation Committee and the New England Organ Bank. Human EC were isolated by collagenase harvest from umbilical cord veins. 5 Human aortic and coronary artery VSMC were isolated by explant outgrowth. 7 Peripheral blood mononuclear cells were collected by leukapheresis from healthy donors. CD4 or CD8 T cells were positively selected from peripheral blood mononuclear cells using Dynal magnetic beads (Invitrogen), and memory T cells were enriched by depleting naïve T cells and recently activated T cells with mouse antihuman CD45RA and human leukocyte antigen-DR antibodies (eBioscience) and antimouse immunoglobulin G magnetic beads. 5
Reagents and Assays
Cytokines included recombinant human tumor necrosis factor (TNF) (R&D Systems), IFN-␥ (Biosource International), and interleukin (IL)-2 (National Cancer Institute). Antibodies included mouse antihuman OX40L, intercellular adhesion molecule-1 (R&D Systems), ICOSL, programmed cell death ligand (PDL)-1, PDL-2 (eBioscience), and leukocyte function-associated antigen-3 (Abcam). LZRSpBMNZ retroviral vectors encoding LacZ or human OX40L, ICOSL, and class II transactivator were used. We have previously described our techniques of cell culture, cell coculture, retrovirus transduction, fluorescence-activated cell sorter analysis, ELISA, and quantitative PCR. 5, 7 Further details are provided in the supplemental material, available online at http://atvb.ahajournals.org.
Statistical Analysis
Comparisons between 2 groups were by t test and between more than 2 groups were by ANOVA. Statistical analyses were performed using Prism 4 software (GraphPad). Probability values were 2-tailed and values of Ͻ0.05 were considered to indicate statistical significance.
Results
VSMC Are Unable to Activate Allogeneic Memory T Cells
We first confirmed previous work that EC and VSMC pretreated with IFN-␥ differ in their abilities to activate allogeneic memory CD4 T cells. [5] [6] [7] Although IFN-␥ stimulated similar expression of MHC class II molecules in both types of vascular cells, EC but not VSMC induced proliferation of CFSE-labeled, allogeneic memory CD4 T cells as indicated by dye dilution after 7 days of coculture ( Figure  1A ). Because IFN-␥ can also induce IDO expression in VSMC at considerably greater levels than in EC or T cells and tryptophan depletion as a result of IDO activity can suppress T-cell clonal expansion, 7 we bypassed the IFN-␥/ IDO effect by upregulating MHC class II molecule expression through retroviral-transduced class II transactivator. However, VSMC still failed to induce allogeneic memory CD4 T-cell proliferation ( Figure 1B ). We also investigated allogeneic CD8 T-cell responses without the need for IFN-␥ pretreatment of vascular cells. Despite similar constitutive levels of MHC class I antigens, proliferating CD8 T cells were only detected in EC but not VSMC cocultures ( Figure  1C ). Addition of neutralizing antibodies to IFN-␥ to block possible effects of endogenous cytokine in VSMC cocultures also did not result in T-cell clonal expansion (data not shown). Similar results were observed with different combinations of EC, VSMC, and T cell donors, ruling out a role for specific allogeneic differences. These data demonstrate immunologic ignorance of VSMC that may result from defects in antigen presentation, costimulation, or stable conjugate formation.
VSMC Do Not Provide Effective Costimulation for Allogeneic Memory T Cells
We specifically tested for vascular cell costimulation function by adding the polyclonal activator, phytohemagglutinin (PHA) to cocultures to cross-link the TCR and provide adhesive interactions (assay principle further explained in A, IFN-␥-pretreated vascular cells were cocultured with CFSE-labeled allogeneic memory CD4 T cells for 7 days. B, class II transactivator-transduced vascular cells were cocultured with CFSE-labeled allogeneic memory CD4 T cells for 7 days. C, Untreated vascular cells were cocultured with CFSE-labeled allogeneic memory CD8 T cells in the presence of exogenous IL-2 for 8 days. MHC class I or II antigen expression (black outline vs gray fill of immunoglobulin G control) by EC and VSMC was analyzed prior to coculture. Proliferating CFSE low T cells were measured at completion of coculture. Data are representative of 3 independent experiments. experimental design section in supplemental data) with or without L-tryptophan supplementation to overcome the effects of IDO activity. Without addition of PHA, there was very little T-cell proliferation from either EC or VSMC cocultures at day 4 ( Figure 2A and 2B), unlike the observable CFSE dilution of T cells in EC cocultures after 7 to 10 days in our standard coculture assays. However, even at this early time point, there was robust proliferation of PHA-stimulated memory CD4 and CD8 T cells in EC cocultures but not in VSMC cocultures. When L-tryptophan was supplemented daily, CFSE low T cells in VSMC cocultures increased, although they did not reach the frequency of that in EC cocultures. Furthermore, the modest amount of CFSE dilution triggered in VSMC cocultures suggested a single or limited division of T cells, whereas the much greater degree of CFSE dilution induced in EC cocultures indicated several rounds of clonal expansion (supplemental Figure I) . Similar results were obtained when mitosis was measured by 5-bromodeoxyuridine incorporation instead of CFSE dilution (supplemental Figure II) . Together, these results are consistent with a defect in costimulation function of VSMC compared with EC.
VSMC Lack Basal or Inducible Expression of OX40L and ICOSL
We examined whether VSMC lack positive costimulators or express negative costimulators in comparison with those of EC at baseline and after cytokine treatment ( Figure 3A) . Leukocyte function-associated antigen-3 expression was constitutive and of similar intensity in both cell types. In contrast, the basal expression of OX40L on EC was more than 5-fold higher than that on VSMC (corrected mean fluorescence intensity [cMFIϭspecific antibody MFIϪcontrol immunoglobulin G cMFI] of 3 donors was 178.0Ϯ49.3 versus 31.7Ϯ22.4, Pϭ0.036). Additionally, the basal and IFN-␥inducible expression of ICOSL was higher on EC compared with that on VSMC (cMFI of 3 donors was 49.2Ϯ4.4 versus 14.5Ϯ10.4, Pϭ0.037), although these levels were relatively low. TNF increased the expression of both OX40L and ICOSL on EC, although not on VSMC ( Figure 3B and 3C). The failure of VSMC to respond to TNF in these assays was selective for the costimulators, because class I MHC molecules were increased under the same conditions (data not shown). Similar basal and IFN-␥-inducible expression of intercellular adhesion molecule-1, an adhesion molecule contributing to immunologic synapse formation and T-cell activation, was seen on EC and VSMC. Both vascular cell types also had low basal expression of PDL-2 and similar induction in PDL-1 and PDL-2 expression after IFN-␥ treatment. Although in this particular donor the basal level of PDL-1 on VSMC was higher than on EC, this difference was not consistent among 3 donors (cMFI was 19.5Ϯ7.9 on EC versus 44.5Ϯ23.2 on VSMC, Pϭ0.35). Furthermore, blocking antibodies to PDL-1 or PDL-2 in VSMC cocultures did not activate allogeneic T cells (data not shown). The costimu- lator phenotype of vascular cells suggests that the striking defects in basal or inducible expression of OX40L and ICOSL by VSMC may be a factor in determining their allogenicity.
Inducible Expression of OX40 and ICOS by T Cells in Coculture With Vascular Cells
To determine whether the absence of OX40L and ICOSL on VSMC could be of functional significance in our coculture system, we investigated the expression of their respective receptors on human memory T cells. Because both TCR and costimulation signals can upregulate the expression of OX40 and ICOS, 8 we tested the effects of vascular cells with or without PHA. Polyclonal TCR signals alone upregulated the expression of OX40 and particularly ICOS on memory CD4 and CD8 T cells (supplemental Figure III) . In EC cocultures, there was further induction of the costimulator receptors; the effects were greater for OX40 than for ICOS expression and for CD4 T cells than for CD8 T cells. In VSMC cocultures, there were minimal changes except for OX40 induction on CD8 T cells. These results confirmed that OX40 and ICOS are expressed by activated memory T cells in coculture with vascular cells and that ligation of these receptors may contribute to T-cell activation in such cocultures.
OX40L-Transduced VSMC Induce CD4 T-Cell Cytokine Production and Proliferation
To directly test our hypothesis that differences in OX40L and/or ICOSL expression between EC and VSMC contribute to the different capacities of these cell types to activate allogeneic memory T cells, we generated VSMC transductants expressing these molecules, as well as control transductants expressing LacZ, by means of retroviral vectors. OX40L or ICOSL surface expression on transduced VSMC was comparable with endogenous levels on EC (supplemental Figure IV) . MHC class II molecule expression was achieved by IFN-␥ pretreatment, because VSMC were relatively refractory to repeat transduction with retrovirus encoding class II transactivator.
We then examined the effects of IFN-␥-pretreated VSMC transductants on cytokine production by CD4 T cells at 48 hours of coculture ( Figure 4A ). CD4 T cells alone did not secrete cytokines, whereas CD4 T cells from EC cocultures did. Interestingly, significant levels of IL-2, IFN-␥, and IL-5 were detected from OX40L-VSMC cocultures. In contrast, there was no significant induction of cytokine secretion from LacZ-or ICOSL-VSMC cocultures. IL-10 and IL-17 levels were very low (below the minimum ELISA standards) and inconsistent between VSMC cocultures.
Despite the effect on IL-2 production, OX40L overexpression on VSMC by itself was not sufficient to stimulate allogeneic memory CD4 T-cell proliferation at day 7 of coculture ( Figure 4B and 4C ). However, daily supplementation with L-tryptophan, which had little effect on T-cell proliferation from EC cocultures, resulted in a large increase in CFSE low cells from OX40L-VSMC cocultures and smaller increases from LacZ-and ICOSL-VSMC cocultures. The differences in CD4 T-cell proliferation between OX40L-VSMC versus LacZ-VSMC cocultures reached statistical significance (PϽ0.001). Similar results were obtained when independent cocultures were performed in the presence of PHA as a more specific test of costimulator function ( Figure  4D ). Additionally, proliferating CD4 T cells from OX40L-VSMC cocultures supplemented with L-tryptophan also expressed the IL-2 receptor activation marker, CD25 to a similar extent as from LacZ-EC cocultures (supplemental Figure V) . As a further specificity control, the proliferative effect of OX40L-VSMC transductants on CD4 T cells was inhibited by neutralizing antibody to OX40L (supplemental Figure VI) . In sum, our data demonstrate that overexpression of OX40L, but not ICOSL, provides effective costimulation for VSMC to activate allogeneic memory CD4 T cells when the growth suppressive effects of IDO-mediated tryptophan depletion are prevented.
OX40L-Transduced VSMC Augment CD8 T-Cell Cytokine Production and Proliferation
We next examined the capacity of VSMC overexpressing OX40L or ICOSL to activate allogeneic memory CD8 T cells in coculture. At 48 hours, very little IL-2, IFN-␥, or TNF were produced by CD8 T cells from VSMC transductant cocultures ( Figure 5A ). Because memory CD8 T cells may produce less cytokines than memory CD4 T cells in response to alloantigen, we used PHA to engage the TCR on a larger population of T cells to enhance cytokine production. With increasing doses of PHA, greater cytokine secretion by CD8 T cells was found in all 3 VSMC cocultures, although OX40L-VSMC consistently induced higher levels of cytokines and ICOSL-VSMC had little effect on IL-2 levels compared with LacZ-VSMC.
We also assessed CD8 T-cell proliferation at day 8 of coculture with transduced vascular cells in the presence of a suboptimal concentration of exogenous IL-2 to augment the magnitude of the proliferative responses. Without addition of L-tryptophan, only LacZ-EC induced CD8 T-cell proliferation ( Figure 5B and 5C ). With daily supplementation of L-tryptophan, there was an increased frequency of proliferating T cells from all 3 VSMC cocultures. Similar results were obtained when the cocultures were performed without exogenous IL-2 (to avoid potential masking of transduced costimulator molecule function), although with fewer CFSE low cells even when assessed at a later time point of day 10 ( Figure 5D ). The small differences between CD8 T-cell proliferation induced by OX40L-VSMC versus LacZ-VSMC transductants were enhanced in the absence of IL-2 and reached statistical significance (PϽ0.05). Overall, our experiments demonstrate that OX40L overexpression, although not essential, confers increased costimulatory function to VSMC to activate allogeneic memory CD8 T cells.
Discussion
In this study, we find that: (1) the absence of essential costimulator function combined with the suppressive effects of IDO-mediated tryptophan depletion are the basis as to why VSMC, unlike EC, fail to activate allogeneic memory CD4 and CD8 T cells; (2) in comparison with human EC, human VSMC lack basal or cytokine-inducible expression of OX40L and ICOSL; and (3) retroviral-mediated overexpression of OX40L induces VSMC immunogenicity.
Previous studies have reported that human VSMC, unlike EC, do not activate allogeneic CD4 T cells in coculture, 5-7,9 -11 although once T cells are activated by EC, they are capable of responding to VSMC from the same donor. 6 The latter observation underscores the less stringent costimulation requirements for recently activated T cells compared with resting T cells, and establishes that T cells can recognize antigen presented by VSMC. In our earlier work, we found that VSMC inhibit memory CD4 T-cell responses to allogeneic EC across a transwell due to IFN-␥-inducible IDO expression and tryptophan depletion. 7 Our present work does not provide evidence for additional IFN-␥-inducible immunomodulatory properties of VSMC. Instead, we demonstrate that impaired costimulation function contributes to immunologic ignorance of allogeneic VSMC by T cells. Previous studies have also reported that allogeneic VSMC do not activate CD8 T cells in coculture. 11 A new finding of our study is that tryptophan depletion by VSMC inhibits activation of memory CD8 T cells in addition to that of memory CD4 T cells. Our conclusions regarding the expression of costimulator molecules in human vascular cells may not apply to rodents, as it has been reported that murine VSMC, but not EC, activate CD4 T-cell cytokine production and proliferation. [12] [13] [14] The deficiency in memory CD4 T-cell activation by human VSMC is at least partially rescued by the overexpression of OX40L to similar levels as basal expression on EC. IL-2, IFN-␥, and IL-5 secretion are induced by OX40L-expressing VSMC, and there is no evidence for obvious immune deviation in our assays. Clonal expansion of alloreactive memory CD4 T cells in response to OX40L-VSMC occurs after tryptophan supplementation. These findings are consistent with the known role of OX40L-OX40 signaling in enhancing the production of both T helper 1 and T helper 2 cytokines under certain conditions, in promoting effector and memory CD4 T-cell proliferation and survival, and in regulating the recall response of memory CD4 T cells. [15] [16] [17] Although not essential, OX40L-expressing VSMC also modestly increase cytokine production and proliferation of allogeneic memory CD8 T cells. The role of OX40L-OX40 signaling is less well established for costimulation of CD8 T cells but appears to play a nonredundant role in augmenting memory generation and recall responses by CD8 T cells in some types of immune responses 18, 19 although not others. 20 In line with their action in controlling the extent of T-cell priming following antigen recognition, the expression of OX40 and its ligand is inducible in immune cells. OX40 is not expressed on resting T cells, but is rapidly reinduced on memory T cells following reencounter with antigen, more transiently on CD8 than CD4 T cells. 17 Similarly, there is little basal expression of OX40L on resting professional antigen-presenting cells, eg, dendritic cells, but is rapidly induced by inflammatory signals. 21 In contrast, OX40L has relatively high basal expression on human EC 5 and is expressed by other human cell types, including airway smooth muscle cells. 22 We have confirmed that human VSMC from normal or diseased aortas do not express OX40L in situ (supplemental Figure VII) . The mechanism(s) that prevents the basal or inducible expression of OX40L on VSMC is unknown and is of interest in the basis of medial immunoprivilege.
In contrast to our findings with OX40L, the overexpression of ICOSL in VSMC to levels that mirror endogenous basal expression by EC only modestly increase effector cytokine secretion but do not augment IL-2 production or increase memory CD4 and CD8 T-cell proliferation compared with control LacZ-VSMC transductants. A limitation of our studies to determine the role of ICOSL is its resistance to TNF induction in VSMC. This phenomenon is particularly notable as TNF upregulates the expression of ICOSL more than 10-fold on EC under the same conditions. ICOSL was originally cloned as a TNF-inducible gene. 23 This study and others have shown that TNF can induce surface ICOSL on diverse human cell types, including fibroblasts, EC, and skeletal muscle cells. [23] [24] [25] Similar to that for OX40L, the mechanism(s) preventing ICOSL expression by TNF in VSMC and whether other stimuli can induce ICOSL expression in VSMC are unknown.
In the absence of OX40L and ICOSL expression, other costimulatory molecules may have contributed to the limited proliferation of memory CD4 and CD8 T cells induced by nontransduced VSMC in the presence of PHA and L-tryptophan and to the limited proliferation of memory CD8 T cells induced by LacZ-VSMC transductants after L-tryptophan supplementation. Candidates include leukocyte function-associated antigen-3 and intercellular adhesion molecule-1, which are equivalently expressed on VSMC and EC. 6 We did not examine the expression of B7 molecules, because both VSMC and EC are known to be deficient in these CD28 ligands. 6 Of relevance, memory CD4 T cells are less dependent on costimulation by B7 molecules compared with naïve CD4 T cells. OX40 and ICOS signaling are important for memory T-cell activation and are causally implicated in animal models of disease, 26 but their role in human arterial diseases is not well defined beyond associations linking genetic variants of OX40L and OX40 to myocardial infarction. 27, 28 We have extended the concept of medial immunoprivilege developed in murine viral infection models 4 to describe the well-characterized sparing of the arterial media by leukocytic infiltrates in many inflammatory arterial diseases. A possible barrier to T-cell trafficking through the media is the presence of circumferential elastic fibers between every layer of VSMC. Disruption of elastic laminae by immune cells in advanced atherosclerosis 29 may provide a mechanical explanation for the breakdown in medial immunoprivilege at this stage of the disease. An alternative, although not mutually exclusive, biological explanation of this phenomenon is the regulation of T-cell responses by VSMC. Although direct measurements of tryptophan levels in tissue compartments have not been performed in vivo, the inhibitory properties of VSMC on T-cell activation within the media depend on IDO-mediated effects of this normally unperfused compartment within the arterial wall. 7 The absence of positive costimulators on resident VSMC, demonstrated here, is likely to contribute as well. In certain circumstances, medial immunoprivilege breaks down, resulting in transmural inflammation as seen in inflammatory aneurysms. 30 In arterial diseases with more attenuated immune responses, such as graft arteriosclerosis (due to concomitant immunosuppression) and atherosclerosis (due to limited antigenicity of putative autoantigens), intact medial immunoprivilege may prevent transmural vasculitis and full-thickness vessel wall injury and modify the disease process.
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